Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Tax Provisions: 2020-2024

Historic Tax Provisions for Xeris Biopharma Holdings (XERS) over the last 4 years, with Dec 2024 value amounting to -$2.3 million.

  • Xeris Biopharma Holdings' Tax Provisions fell 883.43% to -$3.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$2.5 million, marking a year-over-year decrease of 48.17%. This contributed to the annual value of -$2.3 million for FY2024, which is 81.59% down from last year.
  • Xeris Biopharma Holdings' Tax Provisions amounted to -$2.3 million in FY2024, which was down 81.59% from -$1.2 million recorded in FY2023.
  • Xeris Biopharma Holdings' 5-year Tax Provisions high stood at -$110,000 for FY2020, and its period low was -$2.3 million during FY2024.
  • Over the past 3 years, Xeris Biopharma Holdings' median Tax Provisions value was -$1.4 million (recorded in 2022), while the average stood at -$1.6 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first grew by 12.29% in 2023, then plummeted by 81.59% in 2024.
  • Over the past 4 years, Xeris Biopharma Holdings' Tax Provisions (Yearly) stood at -$110,000 in 2020, then reached -$1.4 million in 2022, then grew by 12.29% to -$1.2 million in 2023, then plummeted by 81.59% to -$2.3 million in 2024.